There is interest in using cannabidivarin for seizure disorder, nausea, long-term swelling (inflammation) in the digestive tract, and other conditions, but there is no good scientific evidence to support these uses.
How does it work ?
Uses & Effectiveness ?
Possibly Ineffective for
- Seizure disorder (epilepsy). Taking cannabidivarin for 2 weeks doesn't appear to reduce seizures in people with poorly controlled seizure disorder.
Insufficient Evidence for
- Nerve pain. Early research suggests that taking cannabidivarin for 4 weeks does not seem to reduce nerve pain in people with HIV.
- A rare, inherited disorder that causes obesity, short stature, and learning disability (Prader-Willi syndrome or PWS).
- A type of inflammatory bowel disease (ulcerative colitis).
- A type of inflammatory bowel disease (Crohn disease).
- Duchenne muscular dystrophy.
- Fragile X syndrome.
- Multiple sclerosis (MS).
- Rett syndrome.
- Other conditions.
Special Precautions and Warnings
We currently have no information for CANNABIDIVARIN (CBDV) overview.
Clinical Trial Results: A double blind, randomized, placebo-controlled, two-part study to investigate the pharmacokinetics, followed by efficacy and safety of GWP42006 as add-on therapy in patients with inadequately controlled focal seizures. European Medicines Agency: EU Clinical Trials Register. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002594-11/results. Accessed December 16, 2019.
Deiana S, Watanabe A, Yamasaki Y, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), ??-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl). 2012;219(3):859-73. View abstract.
Eibach L, Scheffel S, Cardebring M, et al. Cannabidivarin for HIV-Associated Neuropathic Pain: A Randomized, Blinded, Controlled Clinical Trial. Clin Pharmacol Ther. 2020. View abstract.
European Medicines Agency. Public summary of opinion on orphan designation: Cannabidivarin for the treatment of Rett syndrome. Available at: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/17/1921-public-summary-opinion-orphan-designation-cannabidivarin-treatment-rett-syndrome_en.pdf. Accessed December 16, 2019.
European Medicines Agency. Public summary of opinion on orphan designation: Cannabidivarin for treatment of fragile X syndrome. Available at: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/18/1977-public-summary-opinion-orphan-designation-cannabidivarin-treatment-fragile-x-syndrome_en.pdf. Accessed December 16, 2019.
Hill AJ, Mercier MS, Hill TD, et al. Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol. 2012;167(8):1629-42. View abstract.
Hill TD, Cascio MG, Romano B, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol. 2013;170(3):679-92. View abstract.
Huizenga MN, Sepulveda-Rodriguez A, Forcelli PA. Preclinical safety and efficacy of cannabidivarin for early life seizures. Neuropharmacology. 2019;148:189-198. View abstract.
Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci. 2014;5(11):1131-41. View abstract.
Iannotti FA, Pagano E, Moriello AS, et al. Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. Br J Pharmacol. 2019;176(10):1568-1584. View abstract.
Pagano E, Romano B, Iannotti FA, et al. The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. Pharmacol Res. 2019;149:104464. View abstract.
Pretzsch CM, Voinescu B, Lythgoe D, et al. Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. Transl Psychiatry. 2019;9(1):313. View abstract.
Rock EM, Sticht MA, Duncan M, Stott C, Parker LA. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and ?(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. Br J Pharmacol. 2013;170(3):671-8. View abstract.
US Food and Drug Administration. Orphan Drug Designations and Approvals. Available at: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/. Accessed on March 19, 2021.
Vigli D, Cosentino L, Raggi C, Laviola G, Woolley-Roberts M, De Filippis B. Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome. Neuropharmacology. 2018;140:121-129. View abstract.
Zamberletti E, Gabaglio M, Piscitelli F, et al. Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice. J Psychopharmacol. 2019;33(7):894-907. View abstract.
Zamberletti E, Gabaglio M, Woolley-Roberts M, Bingham S, Rubino T, Parolaro D. Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. Front Cell Neurosci. 2019;13:367. View abstract.